核受体4A1(NR4A1)拮抗剂诱导子宫内膜癌中ROS依赖的mTOR信号抑制
本研究探讨NR4A1在子宫内膜癌细胞中的表达与功能,采用Ishikawa和Hec-1B细胞,通过RNA干扰敲低NR4A1及双吲哚衍生NR4A1拮抗剂处理,观察对细胞生长、生存及mTOR信号的影响,并在裸鼠移植瘤中验证。结果显示NR4A1敲低或拮抗剂处理均抑制细胞和肿瘤生长,伴随生长促进及生存基因表达下降和mTOR抑制,提示NR4A1为潜在治疗靶点。
要点
- NR4A1在子宫内膜癌细胞中发挥促癌作用,部分通过调控细胞生长、生存及mTOR信号。
- 双吲哚衍生NR4A1拮抗剂在体外抑制子宫内膜癌细胞生长并诱导mTOR抑制。
- NR4A1拮抗剂在体内抑制子宫内膜移植瘤生长,提示NR4A1为潜在新药靶点。
核心结论
- NR4A1在子宫内膜细胞中显示促癌活性,部分源于调控细胞生长、生存和mTOR信号,双吲哚衍生NR4A1拮抗剂可抑制这些通路及在体肿瘤生长,提示NR4A1为潜在新药靶点。
研究设计与样本
- 研究使用Ishikawa和Hec-1B子宫内膜癌细胞模型,通过RNA干扰(siNR4A1)敲低NR4A1及双吲哚衍生NR4A1拮抗剂处理,检测细胞数量、Annexin V染色和Western blot分析全细胞裂解物,并在携带Hec-1B细胞的裸鼠移植瘤中评估NR4A1拮抗剂对肿瘤生长的影响。
主要发现
- siNR4A1或双吲哚衍生NR4A1拮抗剂处理在体外抑制子宫内膜癌细胞生长,在体内抑制子宫内膜肿瘤生长,并伴随生长促进和生存基因表达下降及mTOR抑制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: NR4A1 is overexpressed in many solid tumors, and the objectives of this study were to investigate the expression and functional role of this receptor in endometrial cancer cells and demonstrate that NR4A1 antagonist inhibit mTOR. METHODS: Ishikawa and Hec-1B endometrial cells were used as models to investigate the parallel effects of NR4A1 knockdown by RNA interference (siNR4A1) and treatment with bis-indole-derived NR4A1 ligands (antagonists) on cell growth and survival by determining cell numbers and effects on Annexin V staining. Western blot analysis of whole cell lysates was used to determine effects of these treatments on expression of growth promoting, survival and apoptotic genes and mTOR signaling. Effects of NR4A1 antagonists on tumor growth were determined in athymic nude mice bearing Hec-1B cells as xenografts. RESULTS: siNR4A1 or treatment with bis-indole-derived NR4A1 antagonists inhibited growth of endometrial cancer cells in vitro and endometrial tumors in vivo and this was accompanied by decreased expression of growth promoting and survival genes and mTOR inhibition. CONCLUSIONS: NR4A1 exhibited pro-oncogenic activity in endometrial cells due, in part, to regulation of cell growth, survival and mTOR signaling, and all of these pathways and their associated gene products were inhibited after treatment with bis-indole-derived NR4A1 antagonists. Moreover, these compounds also blocked endometrial tumor growth in vivo demonstrating that NR4A1 is a potential novel drug target for treatment of endometrial cancer.
引用
- Mohankumar K, Li X, Sridharan S, et al. Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer. Gynecol Oncol. 2019. PMID: 31053403. doi:10.1016/j.ygyno.2019.04.678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。